SCHEMBL30280425

SCHEMBL30280425

Cc1ccc(S(=O)(=O)n2c(C(F)F)c(I)c3cc(Br)cnc32)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP3 O14638 1/20 0.39
ENPP1 P22413 1/20 0.39
PTGDR2 Q9Y5Y4 2/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
ALDH3A1 P30838 2/20 0.35
NOD1 Q9Y239 2/20 0.35
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35
GAA P10253 2/20 0.34
LMNA P02545 3/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TP53 P04637 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TSHR P16473 1/20 0.33
PKM P14618 1/20 0.33
PTGS1 P23219 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7513541 0.85 PTGDR2 (0.43) ENPP3ENPP1PTGDR2L3MBTL1ALDH3A1
SCHEMBL30280475 0.83 ENPP3 (0.41) ENPP3ENPP1PTGDR2L3MBTL1ALDH3A1
SCHEMBL30280480 0.83 ENPP3 (0.41) ENPP3ENPP1PTGDR2L3MBTL1ALDH3A1
SCHEMBL30280403 0.81 ENPP3 (0.40) ENPP3ENPP1PTGDR2L3MBTL1ALDH3A1
SCHEMBL20502619 0.80 AGTR1 (0.42) ENPP3ENPP1PTGDR2L3MBTL1ALDH3A1
SCHEMBL31396542 0.80 LMNA (0.37) ENPP3ENPP1PTGDR2LMNAMAPT
SCHEMBL30280408 0.78 ENPP3 (0.38) ENPP3ENPP1PTGDR2L3MBTL1ALDH3A1
SCHEMBL31150779 0.78 ENPP3 (0.42) ENPP3ENPP1PTGDR2L3MBTL1ALDH3A1
SCHEMBL30280419 0.77 KDM4E (0.37) ENPP3ENPP1PTGDR2L3MBTL1ALDH3A1
SCHEMBL30280426 0.76 ENPP3 (0.46) ENPP3ENPP1PTGDR2L3MBTL1ALDH3A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425499-A1 TYRO3 INHIBITORS HALIA THERAPEUTICS INC (US) 2024-12-26 US disclosed
WO-2023064218-A1 TYRO3 INHIBITORS Halia Therapeutics, Inc. (US) 2023-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425499-A1 TYRO3 INHIBITORS TYRO3, TYR, TH ENPP3 1096/4885ENPP1 1738/4885PTGDR2 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.